Summary:
In patients with type 2 diabetes mellitus (T2DM) and stable coronary artery disease, long-term dapagliflozin therapy significantly improved coronary flow reserve (CFR) by 34.4% and reduced epicardial adipose tissue (EAT) thickness by 29.18% compared to placebo in the initial 4-week randomized, double-blind phase prior to crossover, though it was associated with no notable adverse effects reported during the follow-up period.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes mellitus (T2DM) and stable coronary artery disease (CAD) enrolled in the DAPAHEART trial. |
| Intervention | Dapagliflozin 10 mg daily administered for 4 weeks in a randomized phase, followed by long-term treatment up to 4 years post-crossover. |
| Comparison | Placebo during initial 4-week randomized, double-blind period; all placebo patients transitioned to dapagliflozin at study end. |
| Outcome | After 4 years, CFR improved by 34.4% (from 2.15 ± 0.19 to 2.85 ± 0.26, p = 0.001), and EAT thickness decreased by 29.18% (p = 0.03). BMI reductions were noted (p = 0.001), but not significantly correlated with EAT change (R² = 0.0662; p = 0.5), suggesting a weight-independent effect of dapagliflozin on EAT. |
Source: Cinti, Francesca, et al. “Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.” Read article here.
